| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/24/2002 | WO2002005751A1 Composition for topically delivering vitamin c |
| 01/24/2002 | WO2002005749A2 Crf2 ligands in combination therapy |
| 01/24/2002 | WO2002005649A1 Parasiticide and parasitic method for globefish |
| 01/24/2002 | WO2002005647A1 Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics |
| 01/24/2002 | WO2001082872A3 A medicinal aerosol formulation |
| 01/24/2002 | WO2001082861A3 Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters |
| 01/24/2002 | WO2001082780A3 Method for treating cancer, visualizing cell structures, and isolating organelles using organelle crystallizing agents |
| 01/24/2002 | WO2001079526A3 Live cell procedures to identify compounds modulating intracellular distribution of phosphodiesterase (pde) enzymes |
| 01/24/2002 | WO2001078761A3 Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors |
| 01/24/2002 | WO2001070767A3 Therapeutic anti-melanoma compounds |
| 01/24/2002 | WO2001066104A3 Retinoid formulations for aerosolization and inhalation |
| 01/24/2002 | WO2001062239A3 Novel compositions and uses of dictyostatin compounds |
| 01/24/2002 | WO2001060833A3 Motilide compounds |
| 01/24/2002 | WO2001060814A3 Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 01/24/2002 | WO2001060351A3 Nitroacridine/tumor inhibitor compositions |
| 01/24/2002 | WO2001058875A3 Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives |
| 01/24/2002 | WO2001058869A3 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| 01/24/2002 | WO2001058410A3 A method of treating colon cancer by administering apigenin, luteolin, diosmetin and crysin |
| 01/24/2002 | WO2001056992A3 Dibenzo (b,f) azepine intermediates |
| 01/24/2002 | WO2001056405A3 A method for maintaining or improving the synthesis of mucins |
| 01/24/2002 | WO2001053268B1 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
| 01/24/2002 | WO2001052892A3 Jak/stat pathway inhibitors and the uses thereof |
| 01/24/2002 | WO2001051515A3 Genes differentially expressed in breast cancer |
| 01/24/2002 | WO2001049822A3 Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy |
| 01/24/2002 | WO2001047506A3 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 01/24/2002 | WO2001045640A3 Barrier-forming composition |
| 01/24/2002 | WO2001038305A3 Novel il-8 receptor antagonists |
| 01/24/2002 | WO2001036977A8 Identification of disease markers involving mass-based-separation |
| 01/24/2002 | WO2001036470A3 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |
| 01/24/2002 | WO2001034768A3 15 human secreted proteins |
| 01/24/2002 | WO2001034547A3 15-hydroxyeicosatetraenoic acid-related compounds and methods of use |
| 01/24/2002 | WO2001034132A3 Use of an aldosterone antagonist for treating restenosis |
| 01/24/2002 | WO2001032910A3 27 human secreted proteins |
| 01/24/2002 | WO2001032655A3 Quinoline and naphthyridine carboxylic acid antibacterials |
| 01/24/2002 | WO2001032627A8 Process of making substituted pyrazoles |
| 01/24/2002 | WO2001032157A3 Pharmaceutical composition comprising a combination of metformin and glibenclamide |
| 01/24/2002 | WO2001032154A3 Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
| 01/24/2002 | WO2001030337A3 Ophthalmic formulation of dopamine antagonists |
| 01/24/2002 | WO2001030336B1 Pharmaceutical formulations comprising resveratrol and use thereof |
| 01/24/2002 | WO2001029037A3 Condensed naphthyridines as hiv reverse transcriptase inhibitors |
| 01/24/2002 | WO2001029000A3 Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| 01/24/2002 | WO2001027107A3 Heterocyclic sodium/proton exchange inhibitors and method |
| 01/24/2002 | WO2001025436A3 Endozepine-like polypeptides and polynucleotides encoding same |
| 01/24/2002 | WO2001023409A8 38 human secreted proteins |
| 01/24/2002 | WO2001023387A3 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
| 01/24/2002 | WO2001023385A3 Novel tropane analogs |
| 01/24/2002 | WO2001023357A3 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists |
| 01/24/2002 | WO2001022936A8 Topical suspension formulations containing ciprofloxacin and dexamethasone |
| 01/24/2002 | WO2001019860A3 Proteins associated with cell differentiation |
| 01/24/2002 | WO2001019855A3 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 01/24/2002 | WO2001017564A3 Enzyme inhibitors |
| 01/24/2002 | WO2001014405A3 Methods of obtaining 2-methoxyestradiol of high purity |
| 01/24/2002 | WO2001008708A3 Enhanced delivery via serpin enzyme complex receptor ligands |
| 01/24/2002 | WO2001006987A3 Transnasal anticonvulsive compositions and modulated process |
| 01/24/2002 | WO2001003682B1 Use of pyridoxin derivatives for the treatment of diabetes and related complications |
| 01/24/2002 | WO2000071107A8 New pharmaceutical combinations for nos inhibitors |
| 01/24/2002 | WO2000069428A3 Anionic polymers as toxin binders and antibacterial agents |
| 01/24/2002 | WO2000066142A3 Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| 01/24/2002 | WO2000059492A3 Anti-tumor activity of vitamin e, cholesterol, taxol and betulinic acid derivatives |
| 01/24/2002 | WO2000056303A3 Treatment of immune diseases |
| 01/24/2002 | WO2000053614A8 Method for producing glyco-conjugates of 20(s)-camptothecin |
| 01/24/2002 | WO2000053168A3 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders |
| 01/24/2002 | WO2000045799A3 Use of substituted isoxazol carboxylic acids and derivatives and novel substances |
| 01/24/2002 | US20020010693 Integrated hangtag production system |
| 01/24/2002 | US20020010550 Pharmacokinetic-based drug design tool and method |
| 01/24/2002 | US20020010357 Heat resistance dosage forms |
| 01/24/2002 | US20020010351 Anticancer agents |
| 01/24/2002 | US20020010344 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
| 01/24/2002 | US20020010343 Compounds having IgE affecting properties |
| 01/24/2002 | US20020010341 Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis |
| 01/24/2002 | US20020010338 Phenyl-keto-imidazolidine thioamide derivatives |
| 01/24/2002 | US20020010337 Stilbene compounds comprising an adamantyl group, compositions and methods thereof |
| 01/24/2002 | US20020010333 Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation |
| 01/24/2002 | US20020010328 Genetic engineering |
| 01/24/2002 | US20020010322 New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments |
| 01/24/2002 | US20020010316 Thiazole derivatives |
| 01/24/2002 | US20020010217 Treatment of inflammation with 2,4,6-trihydroxy-alpha-para-methoxyphenylacetophenone, or its pharmaceutically acceptable derivatives |
| 01/24/2002 | US20020010216 Mixture of norepinephrine reuptake inhibitors and antimuscarinic agents; treating disorders or diseases of the central nervous system, and particularly useful in treating incontinence. |
| 01/24/2002 | US20020010213 Inhibiting membrane transport mediated by the multidrug resistance associated protein MRP in a patient by administering a compound having an amphiphilic anion and a molecular weight of from 300 to 950 daltons. |
| 01/24/2002 | US20020010212 Assay for D-serine transport antagonist and use for treating psychosis |
| 01/24/2002 | US20020010211 Use of alpha-linolenic acid metabolites for treatment or prevention of cancer |
| 01/24/2002 | US20020010210 Pharmaceutical preparation and method for treating cancer |
| 01/24/2002 | US20020010209 Especially for trigeminal neuralgia and neuropathic pain. |
| 01/24/2002 | US20020010208 Dha-pharmaceutical agent conjugates of taxanes |
| 01/24/2002 | US20020010206 Treating cyclooxygenase-2 mediated disorders. |
| 01/24/2002 | US20020010205 Treating alopecia |
| 01/24/2002 | US20020010203 Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
| 01/24/2002 | US20020010202 For treatment of glaucoma and alleviation of elevated intraocular pressure |
| 01/24/2002 | US20020010201 Method for treating restless leg syndrome using pramipexole and clonidine |
| 01/24/2002 | US20020010200 Optically pure (-) amlodipine compositions |
| 01/24/2002 | US20020010198 Treatment of eating disorders, obesity, irritable bowel syndrome, obsessive-compulsive disorders, platelet adhesion, male and female sexual function disorders, restless leg syndrome, osteoarthritis |
| 01/24/2002 | US20020010197 Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity |
| 01/24/2002 | US20020010196 Antiulcer agents, treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison syndrome |
| 01/24/2002 | US20020010195 Mitochondria protecting agents for treating mitochondria associated diseases |
| 01/24/2002 | US20020010194 Administering intranasally a local anesthetic selected from bupivacaine and ropivacaine |
| 01/24/2002 | US20020010193 Ophthalmic compositions for soft contact lens, method of enhancing wettability of soft contact lens, and method of inhibiting terpenoid adsorption |
| 01/24/2002 | US20020010192 Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 01/24/2002 | US20020010191 Topical application of muscarinic and opioid agents for treatment of tinnitus |
| 01/24/2002 | US20020010190 N-heterocyclic derivatives as NOS inhibitors |
| 01/24/2002 | US20020010189 For treatment of sexual disorders, male erectile dysfunction |